• • • •

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

(703) 746-4000 or Fax INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further currespondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless converted below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications. Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) 08/11/2004 26356 7590 Certificate of Mailing or Transmission

I hereby certify that this Foc(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in metapelope addressed to the Mail Stop ISSUE FEE address above, or being facsimals transmitted to the USFTO (703) 746-4000, on the date indicated below. ALCON RESEARCH, LTD. R&D COUNSEL, Q-148 6201 SOUTH FREEWAY FORT WORTH, TX 76134-2099 Dawn Fedyniak (Day 2004 <u>September</u> CONFIRMATION NO. FIRST NAMED INVENTOR ATTORNEY DOCKET NO. FILING DATE APPLICATION NO. 4696 Elias Humberto Hermida Ochoa 02/22/2002 10/082,743 TITLE OF INVENTION: REGENERATION OF ARTICULAR CARTILAGE DAMAGED BY GRADE I AND II OSTEOARTHRITIS BY MEANS OF THE INTRAARTICULAR APPLICATION OF A MIXTURE OF SODIUM HYALURONATE AND CHONDROITIN SULFATE IN A GEL VEHICLE ISSUE FEE PUBLICATION PEE TOTAL FEE(S) DUE DATE DUE SMALL ENTITY APPLN, TYPE \$1330 \$1630 11/12/2004 NO nonprovisional CLASS-SUBCLASS ART UNIT PXAMINER 1623 514-054000 KRISHNAN, GANAPATHY Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list Barry L. Copeland (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, D Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. O "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filled for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (B) RESIDENCE: (CITY and STATE OR COUNTRY) (A) NAME OF ASSIGNED Hunenberg, Switzerland Alcon, Inc. individual Acorporation or other private group entity ogovernment Please check the appropriate assignee category or categories (will not be printed on the patent); 4b. Payment of Fcc(a): 4a. The following fee(s) are enclosed: (i) A check in the amount of the fee(s) is enclosed. Missuc Fee The Payment by credit card. Form PTO-2038 is attached. A Publication Fee (No small entity discount permitted) ☐ Advance Order - # of Copies 5. Change in Entity Status (from status indicated above) O b. Applicant is not claiming SMALL ENTITY status. See, e.g., 37 CFR 1,27(g)(2). ☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The lastic Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered attorney or agent; or the assignee or other party in interest as shown by the recards of the United States Patent and Trudemark Office.

(Authorized Signature)

Barry L. Cope And September 17, 2004 This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND PECS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Parenta, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMIT THIS FORM WITH FEE(S)

PTOL-85 (Rev. 07/04) Approved for use through 04/30/2007.

OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FFB 0 7 2005



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P. D. Des 1450 Alexandris, Vigenia 22313-1450 www.umba.com

NOTICE OF ALLOWANCE AND FEE(S) DUE

26356

7590

09/11/2004

ALCON RESEARCH, LTD. R&D COUNSEL, Q-148 6201 SOUTH FREEWAY FORT WORTH, TX 76134-2099

EXAMINER					
Kristinan,	GANAPATHY				
ART UNIT PAPER NUMBER					

1623

DATE MAILED: 08/11/2004

24/5F

APPLICATION NO.	PILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	1
10/082,743	02/22/2002	Eliss Humberto Hermida Ochon		4696	-

TITLE OF INVENTION: REGENERATION OF ARTICULAR CARTILAGE DAMAGED BY GRADE I AND II OSTEOARTHRITIS BY MÉANS OF THE INTRAARTICULAR APPLICATION OF A MIXTURE OF SODIUM HYALURONATE AND CHONDROFTIN SULFATE IN A GEL VEHICLE

APPLN. TYPE	SMALL ENTITY	issue fee	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE.
nonprovisional	NO	\$1330	\$300	\$1630	11/12/2004

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fec(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when duc.

PTOL-85 (Rev. 07/04) Approved for use through 04/30/2007.

AUG 1 6 2004

R & D COUNSEL



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vigjala 223 12-1450

DATE MAILED: 08/11/2004

APPLICATION NO.	FILE	NG DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/082,743	IMCHINO. IV		Elias Humberto Hermida Ochos		4696	
26356	7590	08/11/2004	•	EXAM	DVER	
ALCON RESEARCH, LTD.			Krishnan, Ganapathy			
R&D COUNSEL 6201 SOUTH FR				ART UNIT	PAPER NUMBER	
FORT WORTH,		-2099		1623		

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (703) 305-1383. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

	Application No.	Applicant(s)		
	10/082,743	HERMIDA OCHOA, ELIAS HUMBERTO		
Notice of Allowability	Examiner	Art Unit		
	Ganapathy Krishnan	1623		
- The MAILING DATE of this communication appears all claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously malled), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	will be mailed in due course. THIS		
1. This communication is responsive to <u>July 15, 2004</u> .				
2. The allowed claim(s) is/are <u>1-5</u> .				
3.				
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB/Paper No./Mail Date	6. Interview Summary Paper No./Mail Da 08), 7. Examiner's Amend 8. Examiner's Statem 9. Other SUF	te		
U.S. Pateni and Tradistrerk Office PTOL-37 (Rev. 1-04)	lotice of Allowability	Part of Paper No./Mall Date 2004080		

Page 2

Application/Control Number: 10/082,743

Art Unit: 1623

83

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

The closest prior art of record, Lindblad teaches the use of hyaluronic acid in less than 2% w/w aqueous solution for the treatment of cartilage degeneration via intrarticular administration. Nocelli teaches the use of sodium chondroitin sulfate in a composition containing 7-10% of it for treatment of articular inflammation in general. The method of treatment of cartilage degeneration via intrarticular implantation of a composition comprising both chondroitin sulfate and hyaluronic acid in the amounts as instantly claimed is not taught or fairly suggested by the prior art of record.

Any comments considered necessary by the applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance".

Any inquiry concerning this communication should be directed to James O. Wilson, Primary Examiner in Art Unit 1623 at 571-272-0661.

VIAMES O. WILSON

TECHNOLOGY CENTER 1600